Core Viewpoint - Fosun Pharma (600196.SH) announced that its subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for the drug Ketorolac patch [1] Group 1 - The approval allows Chaohui Pharmaceutical to initiate Phase III clinical trials for the Ketorolac patch in China once conditions are met [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600196 股票简称：复星医药 编号：临 2025-198 一、概况 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公 司上海复宏汉霖生物技术股份有限公司及其控股子公司就斯鲁利单抗注射液（中国 境内 1商品名：汉斯状®；以下简称"该药品"）新增适应症（即联合含铂化疗新辅 助，在手术后辅助治疗，用于 PD-L1 阳性的、可手术切除的胃癌患者）的药品注册 申请获国家药品监督管理局（以下简称"国家药监局"）受理，并已获纳入优先审 评程序。 二、该药品的基本信息 该药品为本集团（即本公司及控股子公司/单位，下同）自主研发的创新型抗 PD-1 单抗。 上海复星医药（集团）股份有限公司 关于控股子公司药品注册申请获受理的公告 三、对上市公司的影响及风险提示 新增适应症在中国境内进行商业化前尚需（其中主要包括）获得药品注册批准 等。本次药品注册申请获受理不会对本集团现阶段业绩产生重大影响。 由于医药产品的行业特点，药品上市后的具体销售情况可能受到（包括但不限 于 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600196 股票简称：复星医药 编号：临 2025-197 上海复星医药（集团）股份有限公司 关于控股子公司药品获临床试验批准的公告 2 由 IQVIA 提供，IQVIA 是全球医药健康产业专业信息和战略咨询服务提供商；IQVIA CHPA 数据代表中国境 内 100 张床位以上的医院药品销售市场，不同的药品因其各自销售渠道布局的不同，实际销售情况可能与 IQVIA CHPA 数据存在不同程度的差异。 1 三、风险提示 根据中国相关法规要求，该药品尚需在中国境内开展一系列临床研究并经国家 药品审评部门审批通过后，方可上市。根据研发经验，药品研发存在一定风险，例 如临床试验可能会因为安全性和/或有效性等问题而终止。 药品研发及至上市是一项长期工作，存在诸多不确定因素，敬请广大投资者注 意投资风险。 一、概况 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公 司上海朝晖药业有限公司（以下简称"朝晖药业"）收到国家药品监督管理局（以 下简称"国家药监局" ...

证券代码：600196 证券简称：复星医药 公告编号：临 2025-196 上海复星医药（集团）股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 名称 | 汉霖医贸 | | --- | --- | --- | | | 本次担保金额 | 人民币 1,000 万元 | | 被担保方 1 | 截至 2025 年 12 月 12 日， 包括本次担保在内，本集 团实际为其提供的担保 | 人民币 1,000 万元 | | | 余额 是否在前期预计额度内 | 是 □否 □不适用：________ | | | 本次担保是否有反担保 名称 | 被担保方 1 系担保方（复宏汉霖）之 全资子公司，不涉及反担保安排 星诺医药 | | | 本次担保金额 | 人民币 7,000 万元 | | 被担保方 2 | 截至 2025 年 12 月 12 日， 包括本次担保在内，本集 团实际为其提供的担保 余额 | 人民币 23,075 万元 | | | 是否在前期预计额 ...

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for the drug Ketorolac patch [1] Group 1 - The approval allows for the initiation of Phase III clinical trials for the Ketorolac patch in China once conditions are met [1]

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Fuhong Hanlin Biotech has received acceptance from the National Medical Products Administration for a new indication of the drug Surulitinib Injection, which is now included in the priority review process [1] Group 1 - The new indication is for the use of Surulitinib Injection in combination with platinum-based chemotherapy as neoadjuvant therapy and postoperative adjuvant treatment for PD-L1 positive, resectable gastric cancer patients [1] - Surulitinib is an innovative anti-PD-1 monoclonal antibody independently developed by the group [1]

2025年医保药品目录解读（图源：国家医保局） 55岁的徐阿姨觉得自己足够乐观，也足够幸运。2023年8月，她被确诊为弥漫大B淋巴细胞瘤，尽管历经6次化疗，病情却始终未能完全缓解。在医生的建 议下，她最终选择了CAR-T细胞疗法。 CAR-T，全称为Chimeric Antigen Receptor T-Cell Immunotherapy，即嵌合抗原受体T细胞免疫疗法，是一种通过改造患者自身的T细胞，使其能够精准识别 并攻击癌细胞的个性化免疫治疗手段。目前，它仍是一项基于细胞的个性化技术，制备过程复杂，需要先从患者体内提取T细胞，在实验室中进行基因处 理，使其能够识别癌细胞表面的抗原（或标记），并激活其杀死癌细胞的能力，再经扩增后回输至患者体内，从而实现对癌细胞的精准清除。 然而，高昂的费用是这项前沿疗法无法回避的另一重现实。"如果没有百万医疗险，120万元对我而言简直是天文数字。"徐阿姨对时代财经坦言。在医保 及商保报销后，包括化疗、CAR-T治疗期间的自付及其他住院费等在内，她个人仅承担了不到7万元。 但并非所有患者都能如此幸运。CAR-T的昂贵是全球性难题。在美国，其定价通常在37万~50万美元之间， ...

Investment Rating - The report maintains a positive outlook on the overseas pharmaceutical sector, particularly highlighting the recent developments in drug approvals and partnerships [1][5]. Core Insights - The 2025 National Medical Insurance Directory and the first version of the commercial health insurance innovative drug directory were released, adding 114 new drugs, including 111 new drugs approved within the last five years. The success rate for negotiations was 88.19% [1][6]. - Fosun Pharma's subsidiary has licensed an oral GLP-1 drug to Pfizer, with potential milestone payments totaling up to $15.85 billion [2][7]. - The report emphasizes the importance of ongoing clinical trials and the introduction of innovative drugs in the market, which are expected to drive growth in the pharmaceutical sector [10]. Summary by Sections Domestic Policy Developments - The 2025 National Medical Insurance Directory includes 114 new drugs, with 112 successfully negotiated from 127 that entered the bidding process. Most renewal drugs were renewed at original prices, with an average price reduction of 8.4% for 15 drugs [6][7]. Domestic Pharmaceutical Company Updates - Fosun Pharma's subsidiary has signed a licensing agreement with Pfizer for the global development and commercialization of an oral GLP-1R agonist, with an upfront payment of $150 million and potential milestone payments [2][7]. - The approval of clinical trials for HER2 monoclonal antibodies for breast cancer treatment has been granted, indicating progress in innovative cancer therapies [2][7]. - New clinical data for a BCL2 inhibitor was presented, showing promising efficacy and safety in treating various blood cancers [2][7]. Overseas Pharmaceutical Company Updates - Wave Life Sciences reported positive Phase I data for an siRNA drug targeting obesity, showing significant reductions in visceral fat and overall body fat [3][9]. - Structure Therapeutics announced positive results for its oral GLP-1 small molecule, demonstrating substantial weight loss in clinical trials [3][9]. - Roche received EU approval for a CD20 monoclonal antibody for treating lupus nephritis, marking a significant advancement in autoimmune disease therapies [3][9]. Investment Recommendations - The report suggests focusing on innovative drugs and companies with active business development opportunities, particularly those with promising clinical pipelines [10].

Core Viewpoint - Southbound funds have increased their holdings in Fosun Pharma (02196.HK) by 499,500 shares on December 11, with a total net increase of 1,437,000 shares over the last five trading days and 1,806,000 shares over the last twenty trading days [1] Company Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is primarily engaged in the research, manufacturing, and sales of pharmaceutical products [1] - The company operates through five segments: - Pharmaceutical segment focuses on innovative drugs, mature pharmaceutical products, and vaccine business - Medical devices and diagnostics segment involves the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic medical beauty devices - Healthcare services segment operates an integrated online and offline medical service platform - Pharmaceutical distribution and retail segment is involved in the wholesale and retail of pharmaceutical products - Other segments engage in various pharmaceutical-related businesses [1] Shareholding Structure - As of now, southbound funds hold 316 million shares of Fosun Pharma, accounting for 57.28% of the company's total issued ordinary shares [1]

Core Viewpoint - Fosun Pharma's subsidiary, Guilin Pharmaceutical Co., has received approval from the National Medical Products Administration for the registration of sodium foscarnet injection, expanding the company's product line [1] Group 1: Product Approval - The approved indications for the drug include treatment for (1) cytomegalovirus retinitis in AIDS patients and (2) acyclovir-resistant mucocutaneous infections in immunocompromised patients [1] Group 2: Business Impact - The approval of this drug will further enrich the product portfolio of the company, enhancing its market position in the pharmaceutical industry [1]